Multiple Molecular Subtypes of Triple-Negative Breast Cancer Critically Rely on Androgen Receptor and Respond to Enzalutamide In Vivo

Triple-negative breast cancer (TNBC) has the lowest 5-year survival rate of invasive breast carcinomas, and currently there are no approved targeted therapies for this aggressive form of the disease. The androgen receptor (AR) is expressed in up to one third of TNBC and we find that all AR(+) TNBC p...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Mol Cancer Ther
Autores principales: Barton, Valerie N., D’Amato, Nicholas C., Gordon, Michael A., Lind, Hanne T., Spoelstra, Nicole S., Babbs, Beatrice L., Heinz, Richard E., Elias, Anthony, Jedlicka, Paul, Jacobsen, Britta M., Richer, Jennifer K.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2015
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4534304/
https://ncbi.nlm.nih.gov/pubmed/25713333
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-14-0926
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares